Sinha Manish D, Azukaitis Karolis, Sladowska-Kozłowska Joanna, Bårdsen Tonje, Merkevicius Kajus, Karlsen Sletten Ida Sofie, Obrycki Łukasz, Pac Michał, Fernández-Aranda Fernando, Bjelakovic Bojko, Jankauskiene Augustina, Litwin Mieczysław
Department of Paediatric Nephrology, Evelina London Children's Hospital, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom.
Kings College London, London, United Kingdom.
Front Cardiovasc Med. 2022 Oct 31;9:993513. doi: 10.3389/fcvm.2022.993513. eCollection 2022.
Left ventricular hypertrophy (LVH) is the main marker of HMOD in children and young people (CYP). We aimed to assess the prevalence of LVH and its determinants in CYP with primary hypertension (PH).
A meta-analysis of prevalence was performed. A literature search of articles reporting LVH in CYP with PH was conducted in Medline, Embase, and Cochrane databases. Studies with a primary focus on CYP (up to 21 years) with PH were included. Meta-regression was used to analyze factors explaining observed heterogeneity.
The search yielded a total of 2,200 articles, 153 of those underwent full-text review, and 47 reports were included. The reports evaluated 51 study cohorts including 5,622 individuals, 73% male subjects, and a mean age of 13.6 years. LVH was defined as left ventricle mass index (LVMI) ≥ 95th percentile in 22 (47%), fixed cut-off ≥38.6 g/m in eight (17%), sex-specific fixed cut-off values in six (13%), and miscellaneously in others. The overall prevalence of LVH was 30.5% (95% CI 27.2-33.9), while heterogeneity was high ( = 84%). Subgroup analysis including 1,393 individuals (76% male subjects, mean age 14.7 years) from pediatric hypertension specialty clinics and LVH defined as LVMI ≥95th percentile only (19 study cohorts from 18 studies), reported prevalence of LVH at 29.9% (95% CI 23.9 to 36.3), and high heterogeneity ( = 84%). Two studies involving patients identified through community screening ( = 1,234) reported lower LVH prevalence (21.5%). In the meta-regression, only body mass index (BMI) z-score was significantly associated with LVH prevalence (estimate 0.23, 95% CI 0.08-0.39, = 0.004) and accounted for 41% of observed heterogeneity, but not age, male percentage, BMI, or waist circumference z-score. The predominant LVH phenotype was eccentric LVH in patients from specialty clinics (prevalence of 22% in seven studies with 779 participants) and one community screening study reported the predominance of concentric LVH (12%).
Left ventricular hypertrophy is evident in at least one-fifth of children and young adults with PH and in nearly a third of those referred to specialty clinics with a predominant eccentric LVH pattern in the latter. Increased BMI is the most significant risk association for LVH in hypertensive youth.
左心室肥厚(LVH)是儿童和青少年(CYP)高血压介导的器官损害(HMOD)的主要标志。我们旨在评估原发性高血压(PH)患儿和青少年中LVH的患病率及其决定因素。
进行患病率的荟萃分析。在Medline、Embase和Cochrane数据库中检索报告PH患儿和青少年LVH的文章。纳入主要关注PH的CYP(年龄最大21岁)的研究。采用荟萃回归分析解释观察到的异质性的因素。
检索共获得2200篇文章,其中153篇进行了全文审查,纳入了47篇报告。这些报告评估了51个研究队列,包括5622名个体,73%为男性受试者,平均年龄13.6岁。22项研究(47%)将LVH定义为左心室质量指数(LVMI)≥第95百分位数,8项研究(17%)采用固定截断值≥38.6 g/m²,6项研究(13%)采用性别特异性固定截断值,其他研究定义方式各异。LVH的总体患病率为30.5%(95%CI 27.2 - 33.9),而异质性较高(I² = 84%)。亚组分析包括来自儿科高血压专科诊所的1393名个体(76%为男性受试者,平均年龄14.7岁),且仅将LVH定义为LVMI≥第95百分位数(来自18项研究的19个研究队列),报告LVH患病率为29.9%(95%CI 23.9至36.3),异质性也较高(I² = 84%)。两项涉及通过社区筛查确定的患者(n = 1234)的研究报告LVH患病率较低(21.5%)。在荟萃回归中,只有体重指数(BMI)z评分与LVH患病率显著相关(估计值0.23,95%CI 0.08 - 0.39,P = 0.004),并解释了观察到的异质性的41%,但年龄、男性百分比、BMI或腰围z评分则不然。专科诊所患者中主要的LVH表型为离心性LVH(7项研究中779名参与者的患病率为22%),一项社区筛查研究报告向心性LVH占主导(12%)。
至少五分之一的PH儿童和青少年存在左心室肥厚,在转诊至专科诊所的患者中近三分之一存在左心室肥厚,后者以离心性LVH模式为主。BMI升高是高血压青少年LVH最显著的风险关联因素。